Company Monitoring Page for Regeneron

job ratings for Regeneron

01/25/25
industry:
pharmaceutical
company:
Regeneron
job rating:
2
Regeneron is full of foreign industrial spies
12/30/22
industry:
Big Pharma
company:
Regeneron
job rating:
1
My boss is abusive
10/21/17
industry:
Bio-Tech
job title:
Medical Specialist Immunology
company:
Regeneron
job rating:
7
Best company I’ve ever worked for. Best DM, best upper management, focus strongly on older, successful reps.
06/06/17
industry:
Bio pharmaceutical Industry
company:
Regeneron
job rating:
5
I have lived my job until lately. We are being forced to become Moreno like Sanofi. I now want to leave my job and go elsewhere because of it.
05/29/17
industry:
pharma
company:
Regeneron
job rating:
1
culture
01/29/17
industry:
Biotechnology
company:
Regeneron
job rating:
7
Transparency is great! pay is decent. Bonus opportunity is good.

latest headlines for company on cafepharma

Sanofi, Regeneron win FDA nod for Dupixent in chronic hives
BioPharma Dive
Mon, 04/21/25 - 11:13 am
Tags:
Sanofi, Regeneron, Dupixent, FDA, chronic hives
FDA rejection of extended dosing interval is another piece of bad news for Regeneron’s Eylea HD
Fierce Pharma
Mon, 04/21/25 - 10:22 am
Tags:
FDA, Regeneron, Eylea, CRL
Regeneron clears FDA enrollment hurdle for odronextamab review
First Word Pharma
Wed, 02/26/25 - 10:17 pm
Tags:
Regeneron, FDA, odronextamab, follicular lymphoma
Regeneron's gene therapy study shows improved hearing in children with congenital deafness
Contemporary Pediatrics
Mon, 02/24/25 - 05:05 pm
Tags:
Regeneron, gene therapy, DB-OTO, genetic hearing loss, genetic deafness
Regeneron tangles with Sanofi over commercial transparency in long-running Dupixent collaboration
Fierce Pharma
Thu, 02/6/25 - 10:50 pm
Tags:
Regeneron, Sanofi, Dupixent, legal
Regeneron Beats Quarterly Estimates on Eczema Drug Demand; Launches Dividend Program
US News and World Report
Tue, 02/4/25 - 09:25 am
Tags:
Regeneron, Dupixent, earnings, stock buyback
Regeneron patents block biosimilar entry for Eylea
Patently-O
Thu, 01/30/25 - 11:26 pm
Tags:
Regeneron, Eylea, legal, biosimilars, patents
Regeneron Acquisition of Oxular Wipes Out Oxular Workforce
BioSpace
Sun, 01/5/25 - 09:38 pm
Tags:
Regeneron, Oxular, M&A, layoffs
Regeneron acquires UK biotech, adding Oxular's eye disease delivery tech to portfolio
Fierce Biotech
Fri, 01/3/25 - 10:51 am
Tags:
Regeneron, M&A, Oxular, retinal disease
Regeneron anticoagulant bests enoxaparin, matches Eliquis in phase 2 trial
Fierce Biotech
Thu, 12/19/24 - 11:31 am
Tags:
Regeneron, REGN7508, anticoagulants, enoxaparin, Eliquis, clinical trials
Regeneron, Bayer Build Retinal Vein Occlusion Case for Eylea as Biosimilar Pressure Mounts
BioSpace
Wed, 12/18/24 - 11:12 am
Tags:
Regeneron, Bayer, retinal vein occlusion, Eyelea
Regeneron’s R&D approach scores dual wins against Alexion’s Ultomiris and in lymphoma
Pharma Voice
Thu, 12/12/24 - 11:33 am
Tags:
ASH 2024, Regeneron, lymphoma, Alexion, Ultomiris
FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease
Benzinga
Fri, 11/15/24 - 11:15 am
Tags:
Regeneron, Sanofi, Dupixent, FDA, chronic spontaneous urticaria
Regeneron Reports Mixed Q3 Sales as Eylea Franchise Remains Under Pressure
BioSpace
Fri, 11/1/24 - 10:54 am
Tags:
Regeneron, Eylea, earnings
Regeneron loses bid to block Amgen's Eylea biosimilar launch in US
Reuters
Tue, 10/22/24 - 11:30 pm
Tags:
Regeneron, Amgen, biosimilars, Eylea
Regeneron takes the long-haul approach to oncology, stumbles and all
Pharma Voice
Thu, 10/10/24 - 09:52 am
Tags:
Regeneron, cancer, oncology, Libtayo
FDA, after delay, clears Regeneron and Sanofi drug for COPD
BioPharma Dive
Mon, 09/30/24 - 09:25 am
Tags:
Regeneron, Sanofi, Dupixent, COPD, FDA
Sanofi's Dupixent scores double COPD win in US, China
Pharmaphorum
Mon, 09/30/24 - 09:16 am
Tags:
Sanofi, Regeneron, Dupixent, COPD, China
Regeneron's stock drops as it loses bid to block Amgen's Eylea biosimilar
Fierce Pharma
Tue, 09/24/24 - 11:56 am
Tags:
Regeneron, Amgen, legal, biosimilars, Eylea
ESMO 2024: Regeneron’s melanoma combo therapy benefit continues beyond two years
Clinical Trials Arena
Mon, 09/16/24 - 09:46 am
Tags:
ESMO, Regeneron, melanoma, clinical trials, fiablimab

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.